申请人:Huang Xizhong
公开号:US20140023661A1
公开(公告)日:2014-01-23
The present invention relates to a pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an IGF1R inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of therapeutically effective amounts of such inhibitors to a subject in need thereof, and uses of such combination for the treatment of cancer.
本发明涉及一种药物组合物,包括一种α-异构体特异性磷脂酰肌醇3-激酶抑制剂化合物,例如(S)-吡咯烷-1,2-二羧酸2-酰胺1-(4-甲基-5-[2-(2,2,2-三氟-1,1-二甲基乙基)-吡啶-4-基]-噻唑-2-基}-酰胺),或其药学上可接受的盐,以及一种IGF1R抑制剂(例如IGF1R抑制剂抗体A或其变体或衍生物),一种包含该组合物的药物组合物,治疗癌症的方法包括向需要该药物的受试者施用治疗有效量的这些抑制剂,以及使用该组合物治疗癌症的用途。